Anuh Pharma Limited reported a net profit of ₹114.25 lakh for the quarter ended June 30, 2026, rising 37.6% year-on-year from ₹83.01 lakh in Q1FY26. Revenue from operations increased 3.9% to ₹1,938.10 lakh, up from ₹1,864.79 lakh in the prior year period. The improvement in profitability was driven by an expansion in EBITDA margin, which widened to 9.99% from 7.34% a year ago, despite a modest revenue growth trajectory.

The Board of Directors approved the unaudited financial results on August 7, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subjected to a limited review by Jayantilal Thakkar & Co., the statutory auditors of the company. Dilip J. Thakkar, Partner at Jayantilal Thakkar & Co., issued the independent auditor’s review report confirming that the statement discloses information required under the Listing Regulations.

In addition to the financial results, the Board addressed shareholding pattern disclosures. Three members of the Promoter Group — Vikram Kirtilal Shah, Kiran Piyush Shah, and Kinjal Siddharth Jhaveri — withdrew their earlier applications for reclassification from the ‘Promoter’ category to the ‘Public’ category under Regulation 31A of the SEBI LODR Regulations, 2015. These shareholders will continue to be classified as part of the Promoter Group. Collectively, they hold 8,31,748 equity shares, representing 0.83% of the total shareholding.

The company also adopted a revised Policy on Related Party Transactions during the meeting, which is available on its website. All per-share figures in the financial results reflect the impact of the 1:1 bonus share issuance approved by shareholders in September 2025 and allotted on July 16, 2025. The paid-up equity share capital stands at ₹5,011.20 lakh following the bonus issue.

Financial Performance Highlights

What the Numbers Show

The divergence between revenue growth and margin expansion suggests improved operational efficiency or favorable input cost dynamics in Q1FY27. While revenue grew by only 3.9%, EBITDA surged 41.5%, indicating that cost savings or higher pricing power contributed significantly to the bottom line. The adjusted EBITDA margin, however, stood at 9.36%, down from 11.66% in Q4FY26, highlighting volatility when forex gains and other income are excluded. This indicates that core operational margins may face pressure if external factors normalize, warranting close monitoring of cost structures in subsequent quarters.

Anuh Pharma Ltd has scheduled its 66th Annual General Meeting (AGM) for August 12, 2026, at 4:00 p.m. via video conferencing. The meeting will be held to transact business including the adoption of financial statements for the financial year ended March 31, 2026, and the declaration of a final dividend. Shareholders registered on the books of the company as of the cut-off date of August 5, 2026, are eligible to participate and vote.

The register of members and share transfer books will remain closed from August 6, 2026, to August 12, 2026, to determine shareholder entitlement for the dividend. The company has provided a remote e-voting facility, which will commence on August 9, 2026, at 9:00 a.m. and conclude on August 11, 2026, at 5:00 p.m. Members attending the meeting through video conferencing who have not voted remotely may cast their votes electronically during the AGM.

Key AGM Dates

The Notice of the AGM and the Annual Report for the Financial Year 2025-26 will be sent electronically to members and will be available on the company's website. The company has requested members to ensure their email addresses are registered with the company or their depository participants to receive login credentials for e-voting.